Events

Events

2019

August 8, 2019

Cambridge Healthtech Institutes (CHI) 2nd Annual Immuno-Oncology Investing & Partnering Forum

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to present at the CHI’s 2nd Annual Immunno-Oncology Investing & Partnering Forum. Presentation: “Novel Therapeutics and Diagnostics for Cancer Immunotherapy.”
August 6-7, 2019

Cambridge Health Institute’s (CHI) 4th Annual Oncolytic Virus Immunotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to present at the 4th Annual Oncolytic Virus Immunotherapy Summit. Presentation:“Systemic OV Therapy Using Voyager-V1.”
July 21-23, 2019

The 25th Annual Meeting of Japan Society of Gene and Cell Therapy and The International Gene & Cell Therapy Symposium

Tokyo, Japan

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to present at the 25th Annual Meeting of Japan Society of Gene and Cell Therapy and The International Gene & Cell Therapy Symposium. Presentation title: "Intravenous Virotherapy: Inflaming Tumors via the Blood Stream"
April 10-11, 2019

Cambridge Healthtech Institute’s Inaugural Oncolytic Viral Therapy Conference: Engineering, Translational and Clinical Strategies

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Antibody Targeted Viruses: The Next Generation of Oncolytics”.
March 18-22, 2019

Immuno-Oncology Summit Europe

London, UK

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus”.
March 11-13, 2019

Cambridge Healthtech Institute’s 4th Annual Cancer Immunotherapy: Executive Summit

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Voyager-V1: Systemic, single-cycle, trackable oncolytic virotherapy.”
February 11-12, 2019

Bio CEO and Investor Conference

New York, NY

Kah Whye Peng, Ph.D., Vyriad CTO, has been invited to present at the 2019 BIO CEO & Investor Conference. Presentation: “Oncolytic Viruses for IV Cancer Therapy.”
January 7-10, 2019

37th Annual JP Morgan Healthcare Conference

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 37th Annual JP Morgan Healthcare Conference in San Francisco.

2018

December 4-6, 2018

4th Oncolytic Virotherapy Summit

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Vyriad’s Voyager-V1 Program: Pharmacological Enhancement of a Systemically Active, Single Cycle Oncolytic Virus.” Dr. Russell will also co-chair a panel session entitled: Comparing and Contrasting Virus Types.
November 27-29, 2018

30th Annual Piper Jaffray Healthcare Conference

New York, NY

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, attended the 30th Annual Piper Jaffray Healthcare Conference in New York.
August 27-28, 2018

Cambridge Healthtech Institute’s 3rd Annual Oncolytic Virus Immunotherapy: Commercializing the Exciting Potential of Oncolytic Virotherapy

Boston, MA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Progress with Oncolytic Vesicular Stomatitis Viruses”.
June 26-28, 2018

Armed Oncolytic Immunotherapies Summit

Frankfurt, Germany

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, presentation: “Systemic Cancer Therapy Using Oncolytic VSVs: The Voyager Platform” and participate in a Panel Discussion: Explore Novel Approaches to Identify the Most Rational Combinations “
June 1-5, 2018

American Society of Clinical Oncology (ASCO) Annual Meeting

Chicago, Illinois

Alice Bexon, M.D., Vyriad CMO will be attending the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
May 16-19, 2018

18th Annual American Society of Cell & Gene Therapy (ASGCT) meeting

Chicago, IL

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been elected Vice-President of ASGCT. ASGCT has elected four new members to the Board of Directors, including Dr. Stephen J. Russell as new incoming vice president. Dr. Russell will serve a yearlong term as vice president before serving as ASGCT's president-elect and, finally, president through the 2021 annual meeting. Dr. Russell will be Co-Chairing: Clinical Trials Spotlight I at the annual meeting.

Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to present: Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging and Use of Novel Transgenic NIS Reporter Rats for Longitudinal Tracking of Fibrogenesis by High-Resolution Imaging
April 9-12, 2018

International Oncolytic Virus Conference

Oxford, UK

The Great Oncolytic Debate: For the success of oncolytic viruses – single cycle cures or repeat treatments?

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, has been invited to Chair, Innate and collateral adaptive tumor immunity. Dr. Russell will also participate in Steve Russell (Once should be enough!) vs. Alan Melcher (Repeat dosing is crucial!)

Kah-Whye Peng, Ph.D., Vyriad Chief Technology Officer, has been invited to Chair, Translation, imaging and clinical breakthroughs. Dr. Peng will be presenting: Oncolytic virus encoding IFNbeta: optimizing therapeutic index.
January 8-11, 2018

36th Annual JP Morgan Healthcare Conference

San Francisco, CA

Stephen J. Russell, M.D., Ph.D., Vyriad CEO, and Kah-Whye Peng, Ph.D., Vyriad Chief Technical Officer, attended the 36th Annual JP Morgan Healthcare Conference in San Francisco.

2017

2016